Missing: CMC Contrast's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: CMC Contrast's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest CMC Contrast News
Oct 17, 2022
Disclosures: Austrian Federal Ministry for Digital and Economic Affairs; Christian Doppler Research Association; Medical University of Vienna; National Foundation for Research, Technology and Development; and Südtiroler Sanitätsbetriebt supported the study. Preusser reports personal fees from AbbVie, Adastra, AstraZeneca, Bayer, BMJ Journals, Bristol Myers Squibb, CMC Contrast, Daiichi Sankyo, Eli Lilly, Gan & Lee Pharmaceuticals, Gerson Lehrman Group, GSK, Medahead, MedMedia, Merck Sharp & Dohme, Mundipharma, Novartis, Roche, Sanofi and Tocagen outside the submitted work. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact firstname.lastname@example.org . Back to Healio A fourth dose of the COVID-19 vaccine increased humoral immunity among patients with solid and hematologic cancers, according to study results published in JAMA Oncology. However, passive immunization with the long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld; AstraZeneca) did not appear effective against omicron sublineages BA.1 and BA.4, researchers noted. “We recommend a fourth COVID-19 vaccine dose to our patients with solid and hematologic cancers, based on our findings,” researcher Matthias Preusser, MD, told Healio. Source: Adobe Stock Background and methods “We and other groups showed earlier this year that a third vaccination dose increased humoral immunity against COVID-19 in patients with cancer ,” Matthias Preusser, MD, professor of medical oncology and head of the clinical division of oncology at Medical University of Vienna, told Healio. “However, new virus variants of concern keep emerging and are a particular threat to immunocompromised patients, such as those with cancer. We therefore sought to investigate whether a fourth vaccine dose, or antibody-based preexposure prophylaxis, was capable of increasing the immunity in this patient population.” Matthias Preusser Preusser and colleagues compared antibody levels against the receptor-binding domain of the spike protein of COVID-19 hu-1 and omicron sublineages BA.1 or BA.4 among 72 patients (median age, 74 years; 65.3% men) with cancer who received a fourth dose of COVID-19 vaccination (n = 54) or tixagevimab and cilgavimab (n = 18). Most of those who received the fourth vaccination (n = 33) had hematologic malignant neoplasms, whereas 21 had solid tumors. Investigators also assessed the inhibition of the interaction between receptor-binding domains and the receptor angiotensin-converting enzyme 2. Findings Results showed median anti-receptor-binding domains increased from before to after fourth vaccination against omicron sublineages BA.1 (0.154 optical density to 0.969 optical density; P = .02) and BA.4 (0.245 to 0.966; P = .02) among patients with hematologic malignant neoplasms undergoing B cell–targeted therapy. Of note, researchers observed no other differences in antibody levels among those with other hematologic diseases. Among those with solid malignant neoplasms, researchers identified pronounced increases in median anti-receptor-binding domains before vs. after the fourth vaccination dose against variants hu-1 (1.157 optical density vs. 1.438 optical density; P = .02), BA.1 (0.721 vs. 1.026; P = .003) and BA.4 (0.556 vs. 1.22; P = .002). Moreover, the potential inhibition of the interaction between receptor-binding domains and the receptor angiotensin-converting enzyme 2 appeared higher after the fourth vaccination dose among patients with hematologic disease and solid tumor cancers, especially for sublineages BA.1 and BA.4, according to the researchers. Researchers further observed median inhibition of receptor-binding domains and the receptor angiotensin-converting enzyme 2 with tixagevimab and cilgavimab of 99.9% for sublineage hu-1, 34.9% for BA.1 and 15.4% for BA.4. “We recommend a fourth COVID-19 vaccine dose to our patients with solid and hematologic cancers, based on our findings,” Preusser said. “However, we discourage passive immunization with tixagevimab and cilgavimab, because we saw very limited blocking activity against currently circulating COVID-19 variants.” Future research Next steps include the examination of the cellular immune response to the fourth vaccination dose to obtain a better understanding of the potential memory effects on the immune system, Preusser said. “In addition, we are planning studies on long-COVID-19 and humoral immune responses to adapted vaccines and a fifth vaccination dose, which is also already being considered in immunocompromised individuals,” he added. For more information
CMC Contrast Frequently Asked Questions (FAQ)
When was CMC Contrast founded?
CMC Contrast was founded in 2000.
What is CMC Contrast's latest funding round?
CMC Contrast's latest funding round is Seed VC.
How much did CMC Contrast raise?
CMC Contrast raised a total of $6.29M.
Who are the investors of CMC Contrast?
Investors of CMC Contrast include Sunstone Capital, resund Healthcare Management and Malmohus Invest.
Who are CMC Contrast's competitors?
Competitors of CMC Contrast include Insight Imaging, Quality Electrodynamics, Esaote, Profound Medical, T2 Biosystems and 11 more.
Compare CMC Contrast to Competitors
Esaote is a producer of medical diagnostic systems, including ultrasound and MRI equipment.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Tursiop Technologies Llc is a medical device company. It had developed the Tt1 General Purpose Coil for use in imaging machines.
Gold Standard Diagnostics (GSD) provides diagnostic solutions that improve lab efficiency and minimize overall costs. Through an extensive product menu, automated instrument platforms, and outstanding customer service, GSD solves real laboratory problems. The result is a seamless laboratory experience achieved through an integrated approach.
Clinical Laboratory Partners is a provider of clinical diagnostic testing services for healthcare providers, both hospitals and private practices, effectively competing in local markets against a range of national and other local clinical diagnostic laboratories.
Pria Diagnostics specializes in low cost, high performance, fluorescent readers based on Pria's NanoFL platform technology. The company forms partnerships with diagnostics companies and manufacturers, enabling them to improve their current test sensitivity, or to create diagnostics solutions for the point of care market. Pria can help users' business expand into the new and rapidly growing segments of diagnostics testing including, per the company, retail clinics, field testing, physician office laboratories, consumer-driven testing. NanoFL is a proven technology which has been commercialized in Pria's first product, the Element home fertility test for men.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.